PRODUCT DETAILS VIEW ALL PRODUCTS

Bactoclav Dry Syrup,625,1000,dispersible tablets

  • Bactoclav Dry Syrup:Amoxycillin Trihydrate IP equivalent to Amoxycillin 200 mg and Potassium clavulanate IP (as Potassium Clavulanate Diluted IP) equivalent to Clavulanic acid 28.5 mg oral suspension. Amoxycillin Trihydrate IP equivalent to Amoxycillin 400 mg and Potassium clavulanate IP (as Potassium Clavulanate Diluted IP) equivalent to Clavulanic acid 57 mg oral suspension. Bactoclav 625:AmoxycillinTrihydrate IP equivalent to Amoxycillin 500 mg and Potassium ClavulanateIP equivalent to Clavulanic acid 125 mg tablet. Bactoclav 1000:AmoxycillinTrihydrate IP equivalanet to Amoxycillin 500 mg and Potassium clavulanate IP equivalent to Clavulanic acid 125 mg tablet. Bactoclav Dispersible Tablet:Amoxycillin Trihydrate IP equivalent to Amoxycillin 250 mg/200mg and Potassium clavulanate IP equivalent to Clavulanic acid 125 mg/28.5 tablet. Bactoclav Drops: AmoxycillinTrihydrate IP equivalent to Amoxycillin 80mg and Potassium clavulanate IP equivalent to Clavulanic acid 11.4 mg
  • For the treatment of bacterialinfections such as sinusitisotitis media, tonsillitis, acuteand chronic bronchitis, skin andsoft tissue infections, pelvic infections, osteomyelitis, postoperative painFor the treatment and management of patients with community acquired pneumonia or acute bacterial sinusitis due to beta lactamase producing pathogens.For the treatment of mild tomoderate bacterial lowerrespiratory tract infections inadult patients. For the treatment of infections due tosusceptible isolates of thedesignated bacteria in the conditionssuch as lower Respiratory TractInfections, Acute Bacterial OtitisMedia, Sinusitis, Skin And SkinStucture Infections, Urinary TractInfections in Children more than 20kg body weight
  • Amoxicillin is a semisynthetic penicillin that inhibits enzymes in the biosynthetic pathway of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death.Clavulanic acid is a beta-lactamase inhibitor structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin
  • The usual adult dose is 1 Bactoclav 625 tablet every 12 hours. For more severe infections and infections of the lower respiratory tract, the dose should be 1 Bactoclav 1000 tablet every 12 hours or 1 Bactoclav 625 tablet every 8 hours. For Dispersible Tablet: The 250-mg tablet of Bactoclav and the 250-mg tablet do not contain the same amount of clavulanic acid (as the potassium salt). The 250-mg tablet of Bactoclav contains 125 mg of clavulanic acid, whereas the 250-mg tablet contains 62.5 mg of clavulanic acid. 250-mg tablet is given every 8 hours Children: Based on the amoxicillin component, Bactoclav Dry Syrup should be dosed as follows in patients aged 12 weeks (3 months) and older:Urinary tract Skin and Soft Tissue: Mild to moderate:25 mg/kg/day in divided doses every 12 hours, Severe: 45 mg/kg/day in divided doses every 12 hours.Lower Respiratory Tract Sinusitis: 45 mg/kg/day in divided doses every 12 hours.The normal duration of treatment was 7 to 10 days. However, in general, treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained.Neonates and children aged < 12 weeks (3 months):Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended dose of Bactoclav is 30 mg/kg/day divided q12h, based on the amoxicillin component
  • Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients. History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam)
  • Before initiating therapy with amoxicillin/clavulanic acid, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other beta-lactam agents. Convulsions may occur in patients with impaired renal function or in those receiving high doses. Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions.Prolonged use may occasionally result in overgrowth of non-susceptible organisms
  • As with all medicines, use should be avoided inpregnancy, especially during the first trimester, unless considered essential by the physician. Maybe administered during the period of lactation
  • Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion ofamoxycillin.Concomitant use of allopurinol during treatment with amoxycillin can increase the likelihood of allergicskin reactions. Mayaffect the gut flora, leading to lower oestrogenreabsorption and reduced efficacy of combined oral contraceptives. In patients receiving mycophenolatemofetil, reduction in pre-dose concentration of the active metabolitemycophenolic acid of approximately 50% has been reported following commencement of oral amoxicillin plus clavulanic acid
  • The most commonly reported adverse drug reactions (ADRs) are diarrhoea, nausea and vomiting
  • Anti-Bacterials